SI-BONE(SIBN)

Focus: SI-BONE is a publicly traded medical device company focused on sacroiliac joint (SIJ) fusion solutions, with $139M in FY 2025 revenue and a specialized market position in musculoskeletal care.

Musculoskeletal

Profile data last refreshed 20m ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About SI-BONE

AI assessmentNot Hiring

No open roles listed right now. Follow SI-BONE to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

15 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$139M

Key Products

iFuse Implant System

Sacroiliac Joint Pain / Degenerative Sacroiliitis

Growth

Flagship product driving $139M in FY 2025 revenue with multiple clinical variants (iFuse-3D, TORQ) in post-market studies.

iFuse Bedrock Granite Implant System

Spinal Fusion / Sacroiliitis

Help build intelligence for SI-BONE

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused product portfolio in high-unmet-need sacroiliac joint pain market with proven commercial traction ($139M FY 2025 revenue, +31% YoY growth)
Medical device innovator with multiple iFuse system variants in clinical development targeting SIJ dysfunction, joint disruption, and complex spinal deformity
Public company with stable cash position ($35M) and path to profitability, offering equity upside and career progression in specialized orthopedic space

Watch Out For

Unprofitable despite revenue growth—net loss of $43.3M in FY 2025 raises sustainability concerns if growth stalls or market adoption slows
Minimal active hiring (0 open roles at snapshot) and no disclosed headcount make entry challenging; company scale and team expansion plans unclear
Narrow therapeutic focus entirely on SIJ fusion creates career risk if competitive pressure or reimbursement challenges emerge in this single indication

Generated by Claude from SI-BONE's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Next-generation variant expanding iFuse platform into complex adult spinal deformity and revision surgery indications.